Acquiring Company
Apnimed
Acquired Company
Desitin Arzneimittel GmbH
Cambridge
HamburgManufacturingHealthcareManufacturingBiotechnologyHealth CarePharmaceuticalDescription
Apnimed, Inc. has acquired the exclusive global rights to develop and commercialize sulthiame, a differentiated carbonic anhydrase inhibitor, from Desitin Arzneimittel GmbH. This acquisition will enhance Apnimed's portfolio in treating obstructive sleep apnea (OSA) through its joint venture with Shionogi. Sulthiame has completed successful Phase 2 trials and is approved for use in non-sleep-related diseases outside the US.
Quick answer
Apnimed is acquiring Desitin Arzneimittel GmbH, announced April 25, 2025. Apnimed is based in Cambridge, Massachusetts, United States.
- How much did Apnimed pay for Desitin Arzneimittel GmbH?
- The deal value was not disclosed.
- What does Apnimed do?
- Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective..
- Where are Apnimed and Desitin Arzneimittel GmbH based?
- Apnimed is based in Cambridge, Massachusetts, United States. Desitin Arzneimittel GmbH is based in Hamburg, Hamburg, Germany.
- Who are the decision-makers at Apnimed?
- Fundz holds 1 contact at Apnimed. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel Therapeutics for $45 per share (May 28, 2025)
- AbbVie to acquire Cerevel for $45 per share (April 15, 2025)
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- Roquette acquires IFF Pharma Solutions for growth (May 5, 2025)
- Hikma acquires ANDA for trametinib from Novugen (April 17, 2025)
- Intas Pharmaceuticals acquires UDENYCA from Coherus (April 14, 2025)
Who to call at Apnimed, and when
When Apnimed changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Apnimed raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Apnimed, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Apnimed. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Apnimed makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Desitin Arzneimittel GmbH?
Desitin Arzneimittel GmbH was acquired by Apnimed, based in Cambridge. The deal was reported on April 25, 2025. Apnimed is publicly traded (APMD) and operates in Manufacturing.
When did Apnimed acquire Desitin Arzneimittel GmbH?
Apnimed's acquisition of Desitin Arzneimittel GmbH was reported on April 25, 2025. Apnimed, Inc. has acquired the exclusive global rights to develop and commercialize sulthiame, a differentiated carbonic anhydrase inhibitor, from Desitin Arzneimittel GmbH. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Desitin Arzneimittel GmbH do?
Desitin Arzneimittel GmbH is a pharmaceutical company that develops active pharmaceutical ingredients and specialty medicines focusing on neurological and psychiatric disorders. It is privately held, operating in Manufacturing, and is based in Hamburg.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.